22 / 23
Page 68
allied
academies
J Med Oncl Ther 2017 | Volume 2 Issue 4
Oncology and Biomarkers Summit
November 27-28, 2017 | Atlanta, USA
Annual Congress on
C
oupled with the availability of molecular therapeutic
targetinggenomicallydefinedpopulation,next-generation
sequencing (NGS) based multiplexed genomic profiling has
created a growing interest among cancer specialists and
pharmaceutical companies. Among all, using the adequate
technology platform to identify the right genomic biomarker
and provide treatment options is pivotal in drug discovery
and development, as well as clinical trial design. There
is little doubt that the interest has been prompted by
advances in the use of biomarkers, improvements in NGS
platforms and accumulating paradigms of benefit. There is
much opportunity to pioneer the development of precision
oncology. In this talk, the author will walk the audience
through the evolution of cancer precision medicine in the
search of biomarkers, and the impact to cancer clinical trials
in Asia, as well as business growth potential.
e:
allenlai@actgenomics.comOptimizing next-generation sequencing (NGS) and biomarkers in cancer clinical trials in Asia
Allen Lai
ACT Genomics, Singapore